Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs

Immunotherapy has changed the paradigm of cancer treatments. In this way, several combinatorial strategies based on monoclonal antibodies (mAb) such as anti (a)-PD-1 or anti (a)-PD-L1 are often reported to yield promising clinical benefits. However, the pharmacokinetic (PK) behavior of these mAbs is...

Descripción completa

Detalles Bibliográficos
Autores principales: Zalba, Sara, Contreras-Sandoval, Ana M., Martisova, Eva, Debets, Reno, Smerdou, Christian, Garrido, María Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356959/
https://www.ncbi.nlm.nih.gov/pubmed/32604843
http://dx.doi.org/10.3390/pharmaceutics12060595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356959/
https://www.ncbi.nlm.nih.gov/pubmed/32604843
http://dx.doi.org/10.3390/pharmaceutics12060595

Ejemplares similares